STOCKS TRADE HIGHER WITH U.S. INFLATION DATA IN FOCUS

GameStop shares surge as much as 110% as 'roaring kitty' return adds fuel to rally

AXSM Jan 2025 80.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

11.30

0.00

(0.00%)

As of 11:11AM EDT. Market open.

Loading interactive chart...

Simply Wall St.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Investors in Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) had a good week, as its shares rose 2.0% to close at US$75.68...
GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabu
Zacks
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.